Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NZK5

UPID:
ADA2_HUMAN

ALTERNATIVE NAMES:
Cat eye syndrome critical region protein 1

ALTERNATIVE UPACC:
Q9NZK5; A8K9H4; Q6ICF1; Q86UB6; Q8NCJ2; Q96K41

BACKGROUND:
The protein Adenosine deaminase 2, with alternative naming as Cat eye syndrome critical region protein 1, contributes significantly to extracellular adenosine degradation. This process is vital for modulating various cellular responses. ADA2's interaction with proteoglycans on cell surfaces suggests a broader role in cell proliferation and differentiation beyond its enzymatic activity.

THERAPEUTIC SIGNIFICANCE:
Given ADA2's association with conditions like Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome, and Sneddon syndrome, exploring its function offers promising avenues for therapeutic intervention. The protein's detailed study could unlock new strategies for managing these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.